{"preliminary_commentary":{"by_channel":{"x_thread":10,"podcast":2},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03092323\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"SU2C-SARC032","nct_id":"NCT03092323","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=su2c-sarc032-nct03092323. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"SU2C-SARC032","arms":[{"description":"Neoadjuvant pembrolizumab with concurrent radiotherapy, followed by surgical resection and adjuvant pembrolizumab.","label":"Treatment","type":"EXPERIMENTAL"},{"description":"Neoadjuvant radiotherapy followed by surgical resection.","label":"Standard of Care","type":"NO_INTERVENTION"}],"collaborators":["Stand Up To Cancer","Merck Sharp & Dohme LLC"],"completion_date":{"date":"2028-09-01","type":"ESTIMATED"},"conditions":["Soft Tissue Sarcoma of the Extremity"],"enrollment":{"count":126,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Pembrolizumab","otherNames":["KEYTRUDA®"],"type":"DRUG"}],"last_update":"2023-11-18","lead_sponsor":"Sarcoma Alliance for Research through Collaboration","official_title":"SU2C-SARC032: A Phase II Randomized Controlled Trial of Neoadjuvant Pembrolizumab With Radiotherapy and Adjuvant Pembrolizumab in Patients With High-Risk, Localized Soft Tissue Sarcoma of the Extremity","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2025-09-01","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Disease free survival","timeFrame":"2 Years"}],"references":[{"citation":"Mowery YM, Ballman KV, Hong AM, Schuetze SM, Wagner AJ, Monga V, Heise RS, Attia S, Choy E, Burgess MA, Bae S, Pryor DI, Van Tine BA, Tinoco G, Chmielowski B, Freeman C, Gronchi A, Meyer CF, Dickson MA, Hartner L, Davis LE, Powers BC, Moding EJ, Weinhold KJ, van de Rijn M, Brigman BE, Riedel RF, Kirsch DG. Safety and efficacy of pembrolizumab, radiation therapy, and surgery versus radiation therapy and surgery for stage III soft tissue sarcoma of the extremity (SU2C-SARC032): an open-label, randomised clinical trial. Lancet. 2024 Nov 23;404(10467):2053-2064. doi: 10.1016/S0140-6736(24)01812-9. Epub 2024 Nov 12.","pmid":"39547252","type":"DERIVED"}],"start_date":{"date":"2017-07-19","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Randomized Trial of Pembrolizumab & Radiotherapy Versus Radiotherapy in High-Risk Soft Tissue Sarcoma of the Extremity","url":"https://clinicaltrials.gov/study/NCT03092323"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/su2c-sarc032-nct03092323"}